John W. Day, MD, PhD | Stanford Medicine

Dr. John Day, MD, PhD

Claim this profile

Stanford University

Studies Charcot-Marie-Tooth Disease
Studies Spinal Muscular Atrophy
11 reported clinical trials
10 drugs studied

Area of expertise

1

Charcot-Marie-Tooth Disease

John Day, MD, PhD has run 3 trials for Charcot-Marie-Tooth Disease.

2

Spinal Muscular Atrophy

John Day, MD, PhD has run 3 trials for Spinal Muscular Atrophy. Some of their research focus areas include:

SMN2 positive
5q SMA positive
SMN1 positive

Affiliated Hospitals

Image of trial facility.

Stanford University

Image of trial facility.

Neuromuscular Disorders Program At Stanford University School Of Medicine

Clinical Trials John Day, MD, PhD is currently running

Image of trial facility.

Motor Outcomes Evaluation

for Facioscapulohumeral Muscular Dystrophy

The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and reachable workspace, as well as optional muscle biopsy and wearable device (US participants only).

Recruiting

1 award

N/A

1 criteria

Image of trial facility.

Natural History Study

for Charcot-Marie-Tooth Disease

This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C). The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window

Recruiting

1 award

N/A

10 criteria

More about John Day, MD, PhD

Clinical Trial Related

5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments John Day, MD, PhD has experience with

  • Nusinersen
  • AT845
  • Observational Study
  • None
  • Motor Outcomes To Validate Evaluations In FSHD (MOVE FSHD)
  • BIIB105

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does John Day, MD, PhD specialize in?

Is John Day, MD, PhD currently recruiting for clinical trials?

Are there any treatments that John Day, MD, PhD has studied deeply?

What is the best way to schedule an appointment with John Day, MD, PhD?

What is the office address of John Day, MD, PhD?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security